https://www.selleckchem.com/products/AT7519.html
Five (83%) patients had responses (complete remission n=3). Median time to first response of complete remission/complete remission with incomplete count recovery was 1.0month (range, 0.8-5.5); median overall survival 15.7months (95% confidence interval 6.2, not reached). Venetoclax plus azacitidine was well tolerated and showed high response rates in Japanese patients with acute myeloid leukaemia. Venetoclax plus azacitidine was well tolerated and showed high response rates in Japanese patients with acute myeloid leukaemia. We developed
Like
Comment
Share
